Chantix and cardiovascular events

July 2011
Internal Medicine Alert;7/15/2011 Pharmacology Watch, p2
The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) concerning an increased risk of cardiovascular events in patients with cardiovascular disease who are taking varenicline (Chantix).


Related Articles

  • Strangling the Goose that Lays the Golden Drugs. Miller, Henry I. // Regulation;Summer2007, Vol. 30 Issue 2, p12 

    The author criticizes the U.S. Food and Drug Administration (FDA) for its failure to demonstrate commitment to drug safety. He argues that regulators need to balance patients' access to therapies with ensuring the safety of drugs. The author also believes that the FDA has done little to address...

  • FDA alerts to ongoing cardiovascular safety review of olmesartan.  // Formulary;Jul2010, Vol. 45 Issue 7, p228 

    The author reports that the U.S. Food and Drug Administration is investigating whether the angiotensin II receptor blocker olmesartan is linked to increased cardiovascular mortality. In two randomized controlled trials, patients treated with olmesartan had an increased rate of death from heart...

  • US FDA announces ongoing assessment of CV risk for Stalevo.  // Reactions Weekly;8/28/2010, Issue 1316, p4 

    The article reports on an ongoing investigation being conducted by the U.S. Food and Drug Administration (FDA) of clinical trial data which suggests the association of Stalevo or carbidopa/levodopa/entacapone sue with an increased risk of cardiovascular events, compared with Sinemet of...

  • Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents. Alzayer, Reem; Hughes, Jeffery; Parsons, Richard; Ya Ping Lee // Quality in Primary Care;2010, Vol. 18 Issue 3, p189 

    Aim The aim of this study was to examine the risk of cardiovascular diseases among users of both inhaled (ipratropium bromide or tiotropium bromide) and oral (oxybutynin and propantheline, solifenacin, tolterodine) anticholinergics. Method A retrospective study was undertaken on data obtained...

  • US FDA advises caution for recombinant erythropoietins.  // Reactions Weekly;11/25/2006, Issue 1129, p2 

    The article reports on a Public Health Advisory issued by the U.S. Food and Drug Administration warning healthcare professionals about serious cardiovascular complications in chronic kidney disease patients receiving two kinds of recombinant erythropoietins. Patients are at increased risk for...

  • Extended varenicline treatment in a severe cardiopathic cigarette smoker: a case report. Munarini, Elena; Marabelli, Chiara; Pozzi, Paolo; Boffi, Roberto // Journal of Medical Case Reports;2015, Vol. 9 Issue 1, p1 

    Introduction: Tobacco smoking is the leading cause of cardiovascular morbidity and mortality and quitting tobacco use should be fundamental for cardiovascular patients. Varenicline is a smoking cessation pharmacological therapy able to improve the possibilities to successfully achieve this...

  • Adverse drug reactions increasing - but denied by doctors. J. S. // Foods Matter (USA);May2008, p12 

    The article focuses on the factors that increase the risk of adverse drug reaction (ADR). Based on medical records, the occurrence of ADR has been associated to death for the U.S. Food and Drug Administration has been reported of the 2.6 fold increase between 1998 and 2005. With the conducted...

  • FDA announces ongoing safety review of olmesartan.  // Endocrine Today;Jul2010, Vol. 8 Issue 7, p13 

    The article reports on a review being conducted by the U.S. Food and Drug Administration (FDA) on the possible association between olmesartan and a higher rate for death from a cardiovascular cause in patients with type 2 diabetes.

  • DRUG SAFETY COMMUNICATIONS: PRINCIPLES, PRACTICE, AND EVALUATION. Eby, Michelle // AMWA Journal: American Medical Writers Association Journal;2012, Vol. 27 Issue 4, p160 

    The article focuses on the lecture titled "Drug Safety Communications: Principles, Practice, and Evaluation" given by doctor Laura Pincock during the special session of the U.S. Food and Drug Administration (FDA) at the American Medical Writers Association (AMWA) annual conference. It says that...

  • Ischaemic Colitis in Rheumatoid Arthritis Patients Receiving Tumour Necrosis Factor-α Inhibitors: An Analysis of Reports to the US FDA Adverse Event Reporting System. Salk, Allison; Stobaugh, Derrick; Deepak, Parakkal; Ehrenpreis, Eli // Drug Safety;2013, Vol. 36 Issue 5, p329 

    Background: Tumour necrosis factor-α (TNF-α) inhibitors are immunosuppressants, approved for the treatment and maintenance of rheumatoid arthritis (RA). Immunosuppression has been shown to induce ischaemic colitis (IC) in an animal model; however, a relationship between TNF inhibitors and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics